Urate-lowering therapy for patients with gout on hemodialysis. [PDF]
Int J Rheum Dis, 2022 AbstractObjectiveGout is the most common form of inflammatory arthritis and is caused by deposition of monosodium urate crystals resulting from a high burden of uric acid (UA). High UA burden also has been associated with increased morbidity and mortality in the general population and progression to chronic kidney disease.
Alkilany R, Einstadter D, Antonelli M.
europepmc +4 more sources
Urate-lowering therapy and kidney function
Современная ревматология, 2023 Chronic hyperuricemia (CH) and gout are independent risk factors for decreased kidney function. In the last decade, evidence was accumulating that urate-lowering therapy may be an effective method of slowing down the progression of CH and gout-mediated ...
M. S. Eliseev
doaj +4 more sources
Spinal gout recovery with urate‐lowering therapy: A case report [PDF]
Clinical Case ReportsKey Clinical Message The occurrence of spinal gout resulting in erosion of the superior articular process in patients with low back pain is uncommon, potentially leading to misdiagnosis and inappropriate treatment.
Kunfang Huo +5 more
doaj +4 more sources
Gout Remission as a Goal of Urate-Lowering Therapy: A Critical Review [PDF]
Pharmaceuticals, 2023 Urate-lowering therapies for the management of gout lead to a reduction in serum urate levels, monosodium urate crystal deposition, and the clinical features of gout, including painful and disabling gout flares, chronic gouty arthritis, and tophi.
Adwoa Dansoa Tabi-Amponsah +5 more
doaj +2 more sources
Urate-lowering therapy for heart failure
Современная ревматология, 2019 Heart failure (HF) is one of the major public health problems in developed countries. Hyperuricemia (HU) is often found in patients with chronic HF (CHF) and is a well-known independent predictor for mortality and re-hospitalization for the progression ...
O. V. Zhelyabina, M. S. Eliseev
doaj +3 more sources
Adherence with urate-lowering therapies for the treatment of gout [PDF]
Arthritis Research & Therapy, 2009 Abstract Introduction Adherence to urate-lowering drugs (ULDs) has not been well evaluated among those with gout. Our aim was to assess the level and determinants of non-adherence with ULDs prescribed for gout.
Leslie R. Harrold +6 more
openalex +5 more sources
Design and implementation of a Pacific intervention to increase uptake of urate-lowering therapy for gout: a study protocol [PDF]
International Journal for Equity in Health, 2021 Background Gout is a painful chronic disease which disrupts work and family life and can lead to chronic joint damage. Pacific people in Aotearoa/New Zealand experience significant inequities, with over three times the gout prevalence of the non-Pacific ...
Malakai Ofanoa +8 more
doaj +2 more sources
Variation in serum urate levels in the absence of gout and urate lowering therapy [PDF]
BMC Rheumatology, 2021 Background Previous studies have noted significant variation in serum urate (sUA) levels, and it is unknown how this influences the accuracy of hyperuricemia classification based on single data points.
Andrew Shaffer +4 more
doaj +2 more sources
Prevention of arthritis attacks in the use of urate-lowering therapy in patients with gout
Научно-практическая ревматология, 2019 During the first months after initiation of urate-lowering therapy in patients with gout, the risk of exacerbating arthritis substantially increases, frequently causing them to refuse this treatment.
M. N. Chikina
doaj +3 more sources
Urate lowering therapy in patients starting hemodialysis limit gout flares occurrence: ten years retrospective study [PDF]
BMC NephrologyBackground Uncontrolled gout can cause articular impairment but is also associated with a global and cardiovascular excess mortality, especially in dialysis population.
Alexia Steelandt +7 more
doaj +2 more sources